A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The hypothesis is that the particular richness of ATC's microenvironment in TAMs creates a
unique opportunity for using Tumor Necrosis Factor blockade during chemotherapy and
radiotherapy in order to counteract tumor resistance to therapy.